PMID- 34930687
OWN - NLM
STAT- MEDLINE
DCOM- 20220321
LR  - 20221207
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
VI  - 16
IP  - 1
DP  - 2022 Feb
TI  - Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic 
      foot-related extremity amputation in patients with T2DM: A meta-analysis.
PG  - 156-161
LID - S1751-9918(21)00223-0 [pii]
LID - 10.1016/j.pcd.2021.12.007 [doi]
AB  - AIM: To compare the contribution of sodium-glucose cotransporter-2 inhibitors 
      (SGLT2is) with that of DPP4i or GLP-1ra toward lower extremity amputation rate. 
      METHODS: Electronic databases were searched for articles published on the 
      differences between the rates of lower extremity amputation among patients with 
      type 2 diabetes mellitus (T2DM) undergoing SGLT2i treatment and those undergoing 
      other anti-hyperglycemic agent (dipeptidyl peptidase-4 inhibitors [DPP4is], 
      glucagon-like peptide-1 receptor agonist [GLP-1as], or sulfonylurea [SUs]) 
      treatments. Random-effect models were used to generate data if heterogeneity was 
      detected. RESULTS: Eight studies based on retrospective case-control designs with 
      propensity matching were included. The propensity score-matching method increased 
      credibility. Compared with SGLT2i treatment, DPP4i or GLP-1a treatment tended to 
      result in a higher amputation rate (pooled hazard ratio [HR] = 1.1, 95% 
      confidence interval [CI]: 0.98-1.23), whereas SU treatment resulted in similar 
      amputation rates (pooled HR = 0.92, 95% CI: 0.74-1.13). After excluding the 
      heterogeneous study, the meta-analysis of the remaining studies attained a 
      statistical value (pooled HR = 0.81, 95% CI: 0.65-1.01). CONCLUSION: The study 
      findings suggest that, with respect to diabetic foot-related limb amputations, 
      SGLT2is are not superior to novel anti-hyperglycemic agents (DPP4is and GLP-1as) 
      or other types of oral hypoglycemic agents (SUs). Therefore, SGLT2is may not have 
      significantly positive effects on the prognosis for T2DM patients with 
      complicated diabetic foot.
CI  - Copyright (c) 2021 Primary Care Diabetes Europe. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Du, Yaping
AU  - Du Y
AD  - Department of Endocrinology, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Bai, Lei
AU  - Bai L
AD  - Department of Endocrinology, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Fan, Bingge
AU  - Fan B
AD  - Department of Endocrinology, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Ding, Haixia
AU  - Ding H
AD  - Department of Endocrinology, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Ding, Haiyan
AU  - Ding H
AD  - Department of Endocrinology, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Hou, Lin
AU  - Hou L
AD  - Department of Endocrinology, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Ma, Hongfang
AU  - Ma H
AD  - Department of Endocrinology, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Xing, Na
AU  - Xing N
AD  - Department of Endocrinology, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Wang, Fujun
AU  - Wang F
AD  - Department of Endocrinology, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China. Electronic address: wangfujun139@126.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20211218
PL  - England
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - EC 3.4.14.5 (DPP4 protein, human)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
SB  - IM
MH  - Amputation, Surgical
MH  - *Diabetes Mellitus, Type 2/complications/diagnosis/drug therapy
MH  - *Diabetic Foot/diagnosis/drug therapy/surgery
MH  - Dipeptidyl Peptidase 4
MH  - *Dipeptidyl-Peptidase IV Inhibitors/adverse effects
MH  - Extremities
MH  - Glucagon-Like Peptide 1
MH  - Glucagon-Like Peptide-1 Receptor/agonists
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - Retrospective Studies
MH  - *Sodium-Glucose Transporter 2 Inhibitors/adverse effects
OTO - NOTNLM
OT  - Diabetic foot
OT  - Dipeptidyl peptidase-4 inhibitors
OT  - Glucagon-like peptide-1 receptor agonists
OT  - Sodium-glucose cotransporter-2 inhibitors
OT  - Type 2 diabetes mellitus
EDAT- 2021/12/22 06:00
MHDA- 2022/03/22 06:00
CRDT- 2021/12/21 06:02
PHST- 2021/04/29 00:00 [received]
PHST- 2021/11/15 00:00 [revised]
PHST- 2021/12/06 00:00 [accepted]
PHST- 2021/12/22 06:00 [pubmed]
PHST- 2022/03/22 06:00 [medline]
PHST- 2021/12/21 06:02 [entrez]
AID - S1751-9918(21)00223-0 [pii]
AID - 10.1016/j.pcd.2021.12.007 [doi]
PST - ppublish
SO  - Prim Care Diabetes. 2022 Feb;16(1):156-161. doi: 10.1016/j.pcd.2021.12.007. Epub 
      2021 Dec 18.